This inventor holds 1 USPTO granted patent. Top assignee: Novo Nordisk A/s. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Weimin Wang: Innovator in Nucleic Acid Inhibitor Molecules
Introduction
Weimin Wang is a notable inventor based in Waltham, MA (US). He has made significant contributions to the field of molecular biology, particularly in the development of nucleic acid inhibitor molecules. His innovative work has the potential to impact gene expression and disease treatment.
Latest Patents
Weimin Wang holds a patent for "Double-stranded nucleic acid inhibitor molecules with shortened sense strands." This patent describes double-stranded nucleic acid inhibitor molecules that feature a shortened sense strand with a stem loop structure and an antisense strand. The invention also includes methods and compositions aimed at reducing target gene expression and treating various diseases of interest.
Career Highlights
Weimin Wang is currently employed at Novo Nordisk A/S, a global healthcare company known for its focus on diabetes care and other serious chronic conditions. His work at Novo Nordisk A/S allows him to apply his expertise in molecular biology to real-world health challenges.
Collaborations
Weimin has collaborated with esteemed colleagues such as Bob Dale Brown and Naim Nazef. These collaborations have likely contributed to the advancement of his research and the successful development of his patented technologies.
Conclusion
Weimin Wang's innovative contributions to the field of nucleic acid inhibitors demonstrate his commitment to advancing medical science. His work has the potential to lead to significant breakthroughs in gene therapy and disease treatment.